Loading
A phase 2 trial of ONC206 in pheochromocytoma and paraganglioma, run by Jazz Pharmaceuticals, now recruiting.
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma is a phase 2 interventional study registered as NCT07282587 by Jazz Pharmaceuticals, with 90 participants planned, started 2026-01-02 and due to reach its primary completion in 2028-12-15. Interventions recorded: ONC206, ONC206: Dose 1 and ONC206: Dose 2.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pheochromocytoma and paraganglioma (PPGL) and the tag pipeline.
Shares Pheochromocytoma and paraganglioma (PPGL) and the tag pipeline.
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/